News

diaDexus, PLAC Test for Lp-PLA2 Activity,

The U.S. Food and Drug Administration (FDA) cleared a new screening test that predicts a patient’s risk of future coronary heart disease (CHD) events, such as heart attacks.

Alere, INRatio, INRatio2, PT/INR Monitor system, correction

Alere Inc. has initiated a voluntary correction to inform United States users of the Alere INRatio and INRatio 2 PT/INR Monitor system of certain medical conditions that should not be tested with...

CardioDx Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, "The Use of a Gene Expression Score Showed Clinical...

Akers Biosciences Inc. has signed a feasibility study deal with Konica Minolta Inc. to develop a rapid test for the early detection of myocardial infarction. Heart attacks are the leading cause of...

Singulex Inc. announced the presentation of 10 abstracts at the European Society of Cardiology's (ESC) annual conference, which highlight the clinical utility of single molecule counting...

blood testing, nephrocheck

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk...

August 21, 2014 — diaDexus announced it has received notice from the U.S. Food and Drug Administration (FDA) that an administrative acceptance review was conducted on the traditional 510(k)...

August 12, 2014 — Like clues to a crime, specific molecules in the body can hint at exposure to toxins, infectious agents or even trauma, and therefore help doctors determine whether and how to...

LipoScience Inc. announced the publication of the first large-scale real world study evidencing a link between low LDL-P and reduced cardiovascular disease (CVD) risk.

June 23, 2014 — BG Medicine Inc. earlier this year announced the issuance of patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” by the United State Patent and Trademark...

Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor...

genetic testing for coronary artery disease

Improved understanding of the molecular mechanism of atherogenesis will help identify disease-related pathways and biomarkers that may also help to predict the future risk in asymptomatic...

Singulex Blood Test Clinical Study American Heart Association

Singulex Inc. presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the company’s proprietary ultrasensitive...

April 23, 2014 — Philips Healthcare has completed its first field study for its Minicare handheld cardiac Troponin-I (cTn-I) blood test, demonstrating the platform’s potential to produce...

Data presented from two meta-analyses using the Atherotech Vertical Auto Profile (VAP) lipid panel showed the impact high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP)...

Roughly one out of three children screened for high cholesterol between the ages of 9 and 11 has borderline or high cholesterol, potentially placing them at greater risk for future cardiovascular...

April 10, 2014 — Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs (electrocardiograms) show no...

LipoScience Inc. announced data showing that patients managed to a target LDL particle (LDL-P) number, as measured by LipoScience's NMR LipoProfile test, achieved a 22 to 25 percent greater...

Atherotech Diagnostics Lab opened its patient service center in Sarasota, Fla. 

Without administering a simple blood test in the first few days after surgery, 85 percent of the heart attacks...